PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-17.37%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-66.29%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-101.44%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-101.44%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-63.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-65.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-65.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-2.12%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.12%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
3.02%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-74.43%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-1004.76%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
24.33%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
24.33%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
13.75%
3Y revenue/share CAGR under 50% of AVGO's 60.90%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
192.70%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
192.70%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-83.61%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.60%
3Y dividend/share CAGR above 1.5x AVGO's 38.29%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-2.85%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
6.52%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.34%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.80%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.06%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
7.50%
SG&A growth well above AVGO's 14.12%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.